Wilms tumor (WT) is the most common childhood kidney cancer. To improve risk stratification 36 and identify novel therapeutic targets for patients with WT, we used high-resolution mass spectrometry 37 proteomics to identify urine tumor markers associated with WT relapse. We determined urine proteomes 38 at diagnosis of 49 patients with WT, non-WT renal tumors, and age-matched controls, leading to the 39 quantitation of 6,520 urine proteins. Supervised analysis revealed specific urine markers of renal rhabdoid 40 tumors, kidney clear cell sarcomas, renal cell carcinomas, as well as those detected in cured and relapsed 41
1
Prohibitin is a prognostic marker of relapse and therapeutic target to block chemotherapy resistance 2 in Wilms tumor 3 4
Michael V. Ortiz To validate their prognostic significance and identify improved therapeutic targets of relapsed 112 WT, we assembled an independent cohort of 139 specimens, including 99 favorable histology WT 113 specimens, and 40 age-matched controls (Supplemental Table 1 ). First, we used enzyme-linked 114 immunosorbent assay (ELISA) to measure protein concentration of candidate WT markers in clinical urine 115 specimens. We used commercially available antibodies measure the top 3 urine markers enriched in 116 patients with relapsed WT. While we could not develop specific ELISAs for DACT2 and DAD1 due to the 117 limitations of commercially available antibodies, we confirmed that ELISA for PHB provided accurate 118 measurements of urine PHB, with a linear signal response in the ng/mL range, as determined using 119 purified recombinant PHB (Figure 2A ). Thus, we measured the urine concentration of PHB, as compared 120 to urine creatinine as a control for overall urine concentration (Supplemental Figure 2) . We found that 121 urine PHB was significantly enriched in diagnostic urine specimens from patients who ultimately relapsed 122 (median 1672 ng/mL), as compared to those from patients who were ultimately cured (median 131 123 ng/mL) or age-matched controls (median 218 ng/mL). Using logistic regression, we determined that the 124 PHB urine concentration of 998 ng/mL was significantly associated with WT relapse (odds ratio = 153.3, 125 Figure 2B ). Both urine PHB concentration and urine PHB concentration normalized to urine creatinine (Cr) 126
were statistically significant predictors of relapse, independent of stage and therapy (Figure 2 , 127 Supplemental Figure 2) . Similarly, receiver operating characteristic (ROC) curve analysis showed that 128 urine PHB in patients with WT relapse had the prognostic area under the curve (AUC) of 0.78 (95% 129 confidence interval 0.68-1.0; Figure 2C ). Almost all patients with elevated urine PHB at diagnosis 130 developed WT relapse within 2 years after therapy ( Figure 2D ). We confirmed that urine PHB elevationwas not due to urine concentration, as evident by the lack of statistically significant differences in urine 132 creatinine concentration (Supplemental Figure 2A-C) . We found that urine PHB was significantly elevated 133 in patients with abdominal as compared to lung WT relapse ( Figure 2E ). Indeed, urine PHB exhibited a 134 near perfect prognostic performance for abdominal WT relapse, with the ROC AUC of 0.96 (95% 135 confidence interval 0.91-1.0; Figure 2F ). In all, these results indicate that urine PHB is a significant 136 prognostic marker of WT relapse. 137
Prohibitin is overexpressed in Wilms tumor cells and correlates with tumor stage. 138
To determine whether elevated PHB in WT patient urine samples was due to increased expression 139 of PHB in WT cells, we used immunohistochemistry (IHC) using formalin-fixed paraffin embedded primary 140 patient WT specimens, as compared to adjacent normal kidney tissue. We found that PHB was highly 141 expressed in both favorable histology WT ( Figure 3B and 3E), as well as diffusely anaplastic WT ( Figure 3C  142 and 3F). In agreement with prior studies, we also observed PHB expression in normal kidney tubules 143 ( Figure 3A and 3D) . 18 We assembled a cohort of 59 primary favorable histology WT specimens and 10 144 control non-WT benign and malignant renal samples, uniformly stained for PHB (Supplemental Table 2 ). 145
We scored IHC PHB expression in a blinded manner on the 0 to 3+ scale. Representative images of score 146 levels are shown in Supplemental Figure 3 . Notably, all Wilms tumors expressed PHB from 1+ to 3+ 147 (Supplemental Figures 3D-F) . Consistent with the specific detection of PHB in WT but not other kidney 148 tumors ( Figure 1B) , we found no detectable PHB expression in pre-malignant nephrogenic rests 149 (Supplemental Figure 3A) , embryonal rhabdomyosarcoma (Supplemental Figure 3B) , and clear cell 150 sarcoma of the kidney (Supplemental Figure 3C) . We found that PHB expression in WT correlated with 151 higher tumor stage and increased percentage of tumors with higher PHB expression ( Figure 3G ). 152
We further validated PHB expression using quantitative image densitometry in a second cohort 153 of 38 primary WT patients, including both favorable histology and anaplastic WT (Supplemental Table 4) . 154 Ortiz MV, et al. 9 We observed increased PHB expression in favorable histology WT cells of specimens that ultimately 155 relapsed, as compared with those that were cured with surgery and chemotherapy ( Figure 3H ). On a per-156 cell-basis, PHB expression was increased in favorable histology WT as compared to anaplastic histology 157 WT ( Figure 3I ). We did not observe a statistically significant correlation between PHB mRNA expression 158 and TP53 mutations in diffusely anaplastic WT samples (Supplemental Figure 4) . Likewise, we did not find 159 recurrent mutations or amplification of PHB in a recently analyzed cohort of 117 patient WT specimens. 160 19 Though we found that cellular PHB expression was similar between WT and some normal kidney cells 161 (Supplemental Figure 5A) , we found that WT cells were 12% smaller, with 27% smaller cytoplasm and 11% 162 larger nuclei, as compared to normal kidney cells (Supplemental Figure 5B) Figure 4A ). Normalized to cellular actin, PHB expression was an average 2.9, 171 2.7, and 3.3-fold higher in the WiT49, WTCLS1, and CCG9911 cells, respectively, as compared to normal 172 BJ fibroblasts ( Figure 4B) . 173
Relative overexpression of PHB in WT cells and their relatively smaller size as compared to normal 174 cells suggest that tumor PHB overexpression may be due to its increased expression in specific subcellular 175 compartments, such as mitochondria. 20 Compelled by the finding of PHB staining in the cytoplasm of 176 WT cells (Figure 3) , we used confocal immunofluorescence microscopy to define the subcellularlocalization of PHB in WT cell lines. We observed that most of cellular PHB co-localized with the specific 178 mitochondrial inner membrane marker CoxIV ( Figure 4C ). These findings are consistent with prior studies 179 that identified PHB heterodimerization with PHB2 in association with the inner mitochondrial membrane 180 to regulate mitochondrial morphogenesis.
21-26
Thus, we reasoned that PHB overexpression may 181 contribute to the growth or survival of WT cells. To test this hypothesis, we used three independent short 182 hairpin RNA (shRNA) interference lentiviral constructs to deplete PHB in WT cell lines, as compared to the 183 control shRNA targeting the green fluorescent protein (GFP) which is not expressed (Figure 5 A, B, and C) . 184
We confirmed PHB depletion using Western immunoblotting ( To further elucidate mitochondrial abnormalities in WT, we used transmission electron 222 microscopy to determine the mitochondrial structure of newly diagnosed favorable histology WT 223 Ortiz MV, et al. 12 immediately following nephrectomy. We observed that WT cells exhibited smaller mitochondria with 224 blunted cristae and reduced matrix density, as compared to normal kidney tissue ( Figure 10A-C) . This is 225 consistent with abnormal mitochondrial fission in WT, in agreement with aberrant mitochondrial 226 morphogenesis induced by PHB overexpression, and prior ultrastructural studies of WT. 33 Thus, PHB 227 overexpression causes intrinsic mitochondrial apoptosis resistance, thereby promoting chemotherapy 228 resistance and WT therapy failure. 229
Ortiz MV, et al. 13
Discussion 230
Pathogenesis of childhood solid tumors remains poorly understood. 15 In particular, distinct renal 231 tumors remain difficult to treat, with limited knowledge of prognostic biomarkers and therapeutic targets. 232
In the case of Wilms tumors, the most common childhood kidney tumor, subsets of patients remain 233 incurable, with no effective means to monitor therapy response, stratify existing therapies, and identify 234 improved therapeutic targets. In this context, our findings are significant for several reasons. First, 235
reported urine proteome profiles of diverse kidney tumors provide a rich source of tumor biomarkers and 236 therapeutic targets. Indeed, our recent study of PGBD5, identified in the proteomic profiles of renal 237 rhabdoid tumors, revealed an unanticipated mechanism of solid tumor pathogenesis and improved 238 therapeutic targets.
15-17 239
In the case of Wilms tumors, we found that overexpression of PHB at diagnosis is a prognostic 240 marker of WT relapse. Levels of urinary PHB above 998 ng/mL were found to be significantly associated 241 with relapse in independent cohorts of WT patients (Figures 1 and 2) . PHB overexpression was found to 242 be elevated not only in urine but also in tumor tissue samples in both favorable and anaplastic histology 243 WT, and primarily localized to the mitochondria (Figures 3 and 4) . We found that PHB was required for 244 the growth and survival of WT cells, at least in part by regulating mitochondrial function and apoptosis 245 (Figures 5 and 6 ). Importantly, ectopic overexpression of PHB was sufficient to cause resistance to diverse 246 chemotherapy agents used for clinical treatment of WT. PHB overexpression blocked cytochrome c 247 release from mitochondria, an essential step in the initiation of intrinsic mitochondrial apoptosis (Figures 248 7-9), at least in part by dysregulating mitochondrial cristae (Figure 10 ). Thus, we conclude that PHB 249 overexpression impairs mitochondrial morphogenesis and apoptotic priming, and causes chemotherapy 250 resistance, as schematized in Figure 11 , which can be monitored non-invasively by urine PHB 251 measurements. 252
Ortiz MV, et al. 14 Overexpression of PHB has been described in other tumors, such as breast carcinomas, where 253 somatic amplifications of the PHB gene have been reported in a subset of tumors.
34-36 We did not observe 254 any cases of WT with PHB mutations or amplifications, suggesting that WT overexpression of PHB may 255 involve post-transcriptional mechanisms. PHB expression has been found to be regulated by miR-27a in 256 other tissues [37] [38] [39] [40] , and miR-27a is significantly downregulated in chemotherapy resistant blastemal Wilms 257 tumors. 41 Since several miRNA processing genes are recurrently mutated in subsets of Wilms tumors, it 258 is possible that PHB overexpression is caused by miRNA dysregulation, potentially including miR-27a. 259
Future studies will be needed to determine the mechanisms of potential regulation of PHB expression by 260 miRNAs and causes of its pathogenic overexpression. Likewise, additional studies will be needed to 261 determine the prevalence and function of PHB in highly chemotherapy resistant anaplastic WT. 262
We found urine PHB to be elevated in the majority of favorable histology WT patients whose 263 disease ultimately relapsed ( Figure 2B ). These diagnostic urine PHB levels were generally orders of 264 magnitude higher in patients with ultimately relapsed WT as compared to cured patients ( Figure 2B ). Our findings implicate the interaction between PHB and the mitochondrial proteases OMA1 and 276 YMEL1 in the dysregulation of mitochondrial cristae function and apoptotic cytochrome c release. It is 277 possible that the ring complex formed by PHB and PHB2 affects the OPA1 GTPase that remodels 278 mitochondrial cristae by sequestering the inner mitochondrial membrane OMA1 and YMEL1 proteases 279 within microdomains which are unable to access OPA1.
21,45 As a result, PHB overexpression would impair 280 the release of cytochrome c from mitochondrial cristae, blocking the initiation of mitochondrial apoptosis, 281 as well as altering the dynamics of mitochondrial morphogenesis, which could further contribute to 282 alterations in apoptosis. [28] [29] [30] [31] 46 In addition, although the PHB complex is associated with the inner 283 mitochondrial membrane, it has been shown to interact with BAX and BAK that comprise the apoptotic 284 MOMP pore.
20,47
Thus, in addition to modulating cytochrome c release at crista junctions, PHB 285 overexpression may also impair the formation or function of the MOMP pore. Third, PHB overexpression 286 may impair apoptosis because the properties of the mitochondrial outer membrane govern the ability of 287 the predominantly cytosolic BAX to insert into the mitochondrial outer membrane as well as its ability for 288 subsequent activation by BH3-only proteins. 48, 49 Notably, this impaired BAX membrane insertion would 289 be expected in smaller, hyper-fragmented mitochondria produced as a result of mitochondrial fission. 48 
290
Lastly, PHB overexpression can also affect the energetic and metabolic mitochondrial functions, as well as 291 its other cellular functions, such as regulation of cytosolic signaling. For example, PHB has been reported 292 to interact with the mitochondrial respiratory machinery and thus it is also possible that PHB mediated 293 overexpression co-opts mitochondrial respiration. 26 An analogous mechanism was described wherein 294 inhibitory factor 1 mediated a decrease in OMA1 proteolysis and resulted in impaired Opa1 cleavage by 295 maintaining ATP levels thereby reducing glutathione consumption and inactivating peroxiredoxin 3 during 296 apoptosis. 50 Importantly, given that rocaglamides and aurilide can interact with PHB, it is possible that 297 their derivatives can be developed to specifically interfere with the oncogenic functions of PHB in WT and 298 other tumors. 
Mass Spectrometry 312
Urine specimens were fractionated and the protein composition of the fractions was identified by 313 using high-resolution mass spectrometry as described previously 13 . Briefly, individual five ml urine 314 aliquots were fractionated using ultracentrifugation, protein precipitation, and denaturing polyacrylamide 315 gel electrophoresis, and protein fractions were reduced, alkylated and trypsin digested. Urine protein 316 fractions were subjected to liquid chromatography tandem mass spectrometry using a nanoflow HPLC 317 system (Eksigent, Dublin, CA) coupled to the hybrid linear ion trap-Fourier transform ion cyclotron 318 resonance mass spectrometer (LTQ FT Ultra, Thermo Scientific, Waltham, MA). Resultant spectra were 319 processed to extract the 200 most intense peaks and searched against the human International Protein 320 Index database (version 3.69) by using MASCOT version 2.1.04 (Matrix Science). Assessment of 321 identification accuracy was carried out by searching a decoy database composed of reversed protein 322 sequences of the target IPI database. Only proteins identified on the basis of two or more unique peptides 323
were included in the analysis, at a false discovery rate of <1% at the peptide level. Mass spectrometry 324 data are openly available at PeptideAtlas (http://www.peptideatlas.org/PASS/PASS00248). 325
PHB ELISA 326
Enzyme linked immunosorbent assay (ELISA) against human PHB was constructed using the 327 sandwich capture method. The capture antibody was a rabbit polyclonal antibody against the C-terminaldomain and the detection antibody was a mouse monoclonal antibody paired with the capture antibody 329 and labeled with biotin. The blocking buffer was composed of 1% bovine serum albumin in phosphate-330 buffered saline. Recombinant human prohibitin was produced in E.coli as a single, non-glycosylated His-331 tagged protein. Streptavidin-horseradish peroxidase with tetramethylbenzidine as a substrate was used 332 for detection, as available from Novatein Biosciences (BG-HUM11702; Woburn, MA, United States). 333
Immunohistochemistry and Immunofluorescence 334
Immunohistochemistry was performed using established methods as described previously. and WiT49 cells were cultured in DMEM F-12. All media included 10% fetal bovine serum, 100 U/mLpenicillin, 100 µg/mL streptomycin, and 1% glutamine, as maintained in a humidified atmosphere at 37 o C 351 and 5% CO2. 352
Plasmids 353
For RNA interference, pLKO.1 vectors targeting PHB were obtained from the RNAi Consortium: 354 TRCN0000029204 (referred to as shPHB4), TRCN0000029206 (referred to as shPHB6), and 355 TRCN0000029208 (referred to as shPHB8). PHB was overexpressed using pLX304 vector, as obtained from 356 the DNASU repository. All plasmids were verified by restriction endonuclease mapping and Sanger 357 sequencing, and are available from Addgene (https://www.addgene.org/Alex_Kentsis/). 358
Lentivirus Transduction 359
Lentivirus particles were produced using HEK293T cells with the psPAX2 and pMD2.G packaging 360 plasmids, as described previously. 16 Cell transduction was performed using the multiplicity of infection of 361 10 in the presence of 8 µg/ml hexadimethrine bromide. Transduced cells were selected using puromycin 362 (3 µg/mL) for the pLKO.1 vectors or with blasticidin (3 µg/mL) for the pLX304 vectors. Transduced cells 363 were cloned using limiting dilution. 364
Western Blotting 365
Western blotting was carried out as described.
14 PHB antibody used was a rabbit polyclonal 366 antibody (1:1000, H-80) from Santa Cruz Biotechnology (Dallas, TX, United States). OMA1 antibody used 367 was a mouse monoclonal antibody (1:1000, H-11) from Santa Cruz Biotechnology (Dallas, TX, United 368 States). YME1L antibody used was a rabbit polyclonal antibody (1:1000, AP4882a) from Abgent (Suzhou 369 city, Jiangsu Province, China). Opa1 antibody used was a mouse monoclonal antibody The secondary antibodies used in this study include IRDye 680RD goat anti-rabbit and IRDye 800CW goat 375 anti-mouse secondary antibodies, both at 1:15,000 dilution and obtained from Li-cor (Lincoln, NE, United 376
States). Imaging and quantification was performed using the Li-Cor Odyssey Imaging System (Lincoln, NE, 377
United States). 378
Electron Microscopy 379
Fresh 1 cm 3 pieces of tissue were fixed in 2.5% glutaraldehyde, 4% paraformaldehyde, 0.02% 380 picric acid in 0.1 M sodium cacodylate buffer overnight at 4 o C, washed, and then post fixed with osmium 381 tetroxide reduced with potassium ferricyanide for 1 hour at room temperature, washed, and 382 dehydrated in graded ethanol. Blocks generated using Embed 812 (Electron Microscopy Sciences, 383
Hatfield, PA) resin were cut at 65 nm and mounted on copper grids, stained with uranyl acetate and lead 384 citrate, and imaged using the JEM-1400 electron microscope (JEOL, Tokyo, Japan) as described 385 previously.
386

Statistics 387
Exploratory simple logistic regression models were fit to determine the optimal cut-off point for 388 urine PHB and normalized PHB, which was the ratio of PHB and urine concentrations of creatinine, at 389 which the odds of having relapse was maximized. We also used the Youden index, aimed at maximizing 390 the sensitivity and specificity simultaneously, to find an optimal cut-off point. The Youden index is the 391 maximum of (sensitivity + specificity -1) over all threshold values of PHB and normalized PHB and allows 392 evaluation of a diagnostic test with respect to its true positive and true negative rates. Based on the results of these two criteria, two series of logistic regression models were used to 394 evaluate whether PHB and normalized PHB (dichotomized by the optimal cut-off point) could predict 395
Wilms tumor relapse. The first series was performed for the entire sample, considering either of the two 396 PHB variables only. The second series were performed for patients with Wilms tumor. In addition to the 397 PHB variables, three possible confounders were also included in the multivariate logistic regression 398 
